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Abstract
The identification of recessive disease-causing genes by homozygosity mapping is often restricted by lack of suitable
consanguineous families. To overcome these limitations, we apply homozygosity mapping to single affected individuals
from outbred populations. In 72 individuals of 54 kindred ascertained worldwide with known homozygous mutations in 13
different recessive disease genes, we performed total genome homozygosity mapping using 250,000 SNP arrays. Likelihood
ratio Z-scores (ZLR) were plotted across the genome to detect ZLR peaks that reflect segments of homozygosity by descent,
which may harbor the mutated gene. In 93% of cases, the causative gene was positioned within a consistent ZLR peak of
homozygosity. The number of peaks reflected the degree of inbreeding. We demonstrate that disease-causing homozygous
mutations can be detected in single cases from outbred populations within a single ZLR peak of homozygosity as short as
2 Mb, containing an average of only 16 candidate genes. As many specialty clinics have access to cohorts of individuals from
outbred populations, and as our approach will result in smaller genetic candidate regions, the new strategy of
homozygosity mapping in single outbred individuals will strongly accelerate the discovery of novel recessive disease genes.
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Introduction
The primary causes of most pediatric diseases remain elusive.
However, it is becoming apparent that many pediatric diseases
may represent recessive single-gene (monogenic) disorders. As an
example, it was recently recognized that up to 25% of all cases
with steroid resistant nephrotic syndrome (SRNS) in childhood are
caused by recessive mutations of the NPHS2 gene, although SRNS
had not previously been viewed as a genetic disorder [1–4].
Progress has been made in unraveling the primary causes
(etiologies) of pediatric disorders by identifying recessive disease
genes using positional cloning by homozygosity mapping [5].
Homozygosity mapping is performed by total genome scan with
polymorphic markers in individuals with a recessive disease whose
parents are related. It tests the assumption that a homozygous
mutation in a recessive disease gene is ‘‘identical by descent (IBD)’’
by segregating twice to the affected child from a common ancestor
through both the maternal line and the paternal line (Figure 1). In
addition, homozygosity mapping supposes that a short chromo-
somal segment surrounding the homozygous mutation has not
been recombined by crossing over and that SNP (single nucleotide
polymorphism) markers in a segment surrounding the mutation
will therefore also be homozygous by descent (Figure 1) [5]. This
short segment of homozygosity by descent can then be detected by
multipoint homozygosity mapping as a ‘‘ZLR peak’’ (Figure 2) and
will harbor the sought-after disease gene.
Gene identification by positional cloning holds multiple
promises: i) It directly identifies the primary cause of a disease,
thereby providing a secure starting point for the elucidation of the
related pathogenesis. ii) Positional cloning often leads to the
discovery of novel genes, revealing new mechanisms of cell
physiology and development. iii) Since recessive single-gene
disorders exhibit the strongest possible relationship between
disease cause and disease phenotype, leading to a phenotype in
virtually all individuals with mutations, they provide the most
useful objective for molecular genetic diagnostics [6].
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disorders that are yet to be discovered is most likely in the
thousands [6]. However, more rapid discovery of recessive disease
genes is hampered by the lack of suitable consanguineous families
with multiple affected children. In addition, mapping has resulted
in too many putative loci that contain too many candidate genes
for efficient gene identification.
Considering these impediments to gene discovery, we tested the
hypothesis that SNP arrays may systematically allow gene
identification by homozygosity mapping in single individuals from
non-consanguineous (‘‘outbred’’) populations. If this were possible,
it would offer the following important advantages: i) For any given
disease phenotype, pediatric specialty clinics have access to far more
patients who are from outbred populations and represent single
cases than to patients who are from consanguineous background or
represent sibling cases. ii) Homozygosity mapping in individuals
who are from outbred populations but bear homozygous disease
gene mutations by descent from an unknown distant ancestor may
provide a single genomic candidate region small enough to allow
successful gene identification by mutation analysis.
Methods
Subjects
We obtained blood samples and clinical and pedigree data
following informed consent from individuals with two different
groups of autosomal recessive kidney diseases, nephronophthisis
(NPHP) or steroid resistant nephrotic syndrome (SRNS). Human
Figure 1. Homozygosity mapping of recessive disease genes. An individual with an autosomal recessive disease (filled symbol) whose parents
are consanguineous will very likely be homozygous (identical) by descent for the disease allele (‘‘mutated allele’’), because a rare mutation may
segregate from a common ancestor to the child through both the father’s and mother’s line, rendering the child homozygous for the mutation.
Chromosomal segments surrounding the disease gene locus are shown here with 3 marker positions to either side. Different marker alleles are
represented by different colors. Although for each parent-offspring succession there is an opportunity for a crossing over (dotted line) to occur in the
parents’ gametes, there is a high likelihood that in the affected child consecutive markers surrounding the mutation will not have recombined and
will be identical (homozygous) by descent. This segment of homozygous markers (dotted box) can be detected as a ‘‘cZLR’’ peak in multipoint
evaluation (see Figure S1 and Figure S2), leading to successful mapping of the disease gene. Note also that more remote consanguinity will give more
opportunities for crossing over to occur and will thereby lead in the affected individual to fewer and shorter homozygous intervals that contain the
disease gene (see Figures S2 and S3).
doi:10.1371/journal.pgen.1000353.g001
Author Summary
Many childhood diseases are caused by single-gene
mutations of recessive genes, in which a child has
inherited one mutated gene copy from each parent
causing disease in the child, but not in the parents who
are healthy heterozygous carriers. As the two mutations
represent the disease cause, gene mapping helped
understand disease mechanisms. ‘‘Homozygosity map-
ping’’ has been particularly useful. It assumes that the
parents are related and that a disease-causing mutation
together with a chromosomal segment of identical
markers (i.e., homozygous markers) is transmitted to the
affected child through the paternal and the maternal line
from an ancestor common to both parents. Homozygosity
mapping seeks out those homozygous regions to map the
disease-causing gene. Homozygosity mapping requires
families, in which the parents are knowingly related, and
have multiple affected children. To overcome these
limitations, we applied homozygosity mapping to single
affected individuals from outbred populations. In 72
individuals with known homozygous mutations in 13
different recessive disease genes, we performed homozy-
gosity mapping. In 93% we detected the causative gene in
a segment of homozygosity. We demonstrate that disease-
causing homozygous mutations can be detected in single
cases from outbred populations. This will strongly
accelerate the discovery of novel recessive disease genes.
Mapping in Outbred Individuals
PLoS Genetics | www.plosgenetics.org 2 January 2009 | Volume 5 | Issue 1 | e1000353Figure 2. Homozygous mutations in recessive disease genes are positioned in cZLR peaks. Homozygosity profiles (see Figure S1 and
Methods) are shown for individuals who have a known homozygous mutation in a recessive disease gene causing nephronophthisis (NPHP).
Individuals are (A) from a consanguineous marriage, (B) without known consanguinity but originating from a geographic population with frequent
consanguinity, and (C) originating from an outbred population. Non-parametric LOD scores were calculated with ALLEGRO assuming first-degree
cousin consanguinity of the parents, regardless of actual consanguinity status. ZLR scores (minor allele frequency .0.3) were plotted over genetic
distance across the genome, where chromosomal positions are concatenated from p- to q-arm (left to right). cZLR peaks (arrow heads) exceeding the
empirical cut-off value of 2.0 (dotted line) as described in Figure S1 reflect possible segments of homozygosity by descent, one of which harbors the
homozygous disease gene mutation in each patient (arrows with flags indicate the position of the mutated gene). (A) Individual A14-2 exhibits 28
cZLR peaks. This individual has a known homozygous NPHP3 mutation (flagged position) and is from a consanguineous Venezuelan kindred with 17
documented consanguinity loops [16]. (B) Individual A8-1 exhibits 12 cZLR peaks. This family is not aware of consanguinity but originates from a
geographic region where consanguinity is frequent (Turkey). Note that the homozygosity profile permits exclusion of homozygous mutations from 8
different NPHP loci (NPHP1 and NPHP3-9), which are marked by vertical dashed lines flagged with gene name at the bottom, and directs mutation
analysis to NPHP2, in which the individual carried the disease-causing homozygous mutation. (C) Individual F399-1 exhibits only 1 cZLR peak of
8.25 Mb width, which harbors the disease causing homozygous mutation of NPHP5. This individual originates from a geographic region where
consanguinity is rare (Germany).
doi:10.1371/journal.pgen.1000353.g002
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Institutional Review Board. The diagnoses were made by
nephrologists based on standardized clinical criteria [7,8]. Renal
biopsies were evaluated by renal pathologists. Clinical data were
obtained using standardized questionnaires (www.renalgenes.org).
Mutation Analysis
In 1,069 families with a NPHP-like phenotype, who were
referred to us for mutation analysis from worldwide sources over
the course of 16 years, we performed mutation analysis by direct
exon sequencing in the genes NPHP1 through NPHP9, AHI1, and
MKS3. Additionally, in 404 families with steroid-resistant nephrot-
ic syndrome (SRNS), who were referred to us worldwide for
mutation analysis over the course of 8 years we performed
mutation analysis by direct exon sequencing in the genes NPHS1
(nephrin) and NPHS2 (podocin).
Homozygosity Mapping
We performed genome-wide scans for linkage in 72 individuals
from 54 families, who had a homozygous mutation in any of the
13 genes that cause NPHP or SRNS (NPHP1 through NPHP9,
AHI1, MKS3, NPHS1 or NPHS2). We used single nucleotide
polymorphism (SNP) arrays (GeneChip) from Affymetrix, Inc.
Most individuals (n=40) were examined at 250 K resolution
(Human Mapping 250 K StyI Array), 9 families at 50 K resolution
(50 K Hind Array), and 5 families at 10 K resolution (50 K Xba
Array). Samples were processed, hybridized, and scanned using
the manufacturer’s’ standard methods at the University of
Michigan Core Facility (www.michiganmicroarray.com). As non-
parametric likelihood ratio z-scores (ZLR scores) provide a good
estimate of excess allele sharing [9], and since the GENEHUN-
TER [10] NPL score is conservative [11], we used the ZLR score
implemented in ALLEGRO [12] to detect narrow segments of
homozygosity. Parameters were set for a disease allele frequency of
0.001, and marker allele frequencies for Caucasians as specified by
Affymetrix. We calculated ZLR scores under the hypothesis of
consanguinity, using a standard pedigree structure first cousin
marriage for parents of affected individuals. For single affecteds a
non-existent sibling was included to enable non-parametric
ALLEGRO runs. ZLR scores were plotted over genetic distance
across the entire human genome using the GNUPLOT software
(http://www.gnuplot.info/). In this way, maxima of ZLR scores,
‘‘ZLR peaks’’, are expected to reflect segments of homozygosity by
descent, which may harbor the homozygous mutation of the
recessive disease gene. In the following we will refer to the ZLR
plots as ‘‘homozygosity profiles’’ as described in Figure S1.
Using ALOHOMORA [13], ZLR scores were calculated using
one marker every 100,000 nucleotides of human genomic
sequence under three different conditions, i.e. for minor allele
frequencies of .0.2, .0.3, and .0.4, respectively (Figure S1). In a
small cohort of patients with known homozygous disease-causing
mutations in NPHS2 we established that ZLR peaks, which exceed
the value of 2.0 under two out of the three conditions (minor allele
frequencies of .0.2, .0.3, and .0.4), did in fact contain the
known homozygous disease-causing mutation in this ZLR peak
and exhibited continuous segments of homozygosity upon
haplotype inspection. We therefore refer to peaks that fulfill these
criteria as ‘‘consistent ZLR peaks’’ (‘‘cZLR’’ peaks) (Figure S1).
All ZLR peaks of homozygosity considered ‘‘consistent’’ under
these criteria were also present when using the criterion of 0.1 as
cut off for minor allele frequency.
We later confirmed that in 67 of 72 cases (93%) the homozygous
mutations in the causative gene were positioned within a cZLR
peak (see Results). Thus, cZLR peaks can be utilized to indicate
the position of homozygous mutations in recessive disease genes
with high likelihood. We demonstrate below that cZLR peaks very
rarely occurred in negative control individuals without homozy-
gous mutations (see Results).
Data Bases
Physical distance for SNP markers: genome browser, human,
May 2004 at http://genome.ucsc.edu
Results
Homozygous Mutations Are Frequent in Rare Recessive
Diseases
Homozygosity mapping can only be applied to individuals that
bear homozygous mutations of recessive disease genes. Therefore,
we first evaluated whether in a significant fraction of patients with
mutations in 13 different recessive disease genes the disease was
caused by homozygous rather than compound heterozygous
mutations. We chose 9 different genes (NPHP1-9) [14] that cause
the recessive kidney disorder nephronophthisis (NPHP), 2 genes
(AHI1 and MKS3) causing NPHP-like phenotypes, and 2 genes
(NPHS1 and 2) that cause steroid resistant nephrotic syndrome
(SRNS) [2], as we had access to DNA from worldwide cohorts of
patients with these disorders. NPHP is the most frequent genetic
cause of terminal kidney failure in children and young adults.
Positional cloning of nine responsible genes (NPHP1-9) has
revealed NPHP as a ‘‘ciliopathy’’, relating its pathogenesis to
dysfunction of primary cilia signaling [14].
In a worldwide cohort of 1,069 families with NPHP we detected
the disease-causing mutation in 320 (30%). We excluded from the
analysis 224 families with large deletions of NPHP1, as they are
due to a unique mechanism of genomic DNA rearrangement [15].
In the remaining 96 families, the fraction of homozygous
mutations for each gene was as follows: NPHP1 (2/2; 100%),
NPHP2 (6/11; 55%), NPHP3 (4/6; 66%), NPHP4 (15/20; 75%),
NPHP5 (22/26; 85%), NPHP6 (3/10; 30%), NPHP7 (1/1; 100%),
NPHP8 (6/6; 100%), NPHP9 (1/1; 100%), AHI1 (2/5; 40%), and
MKS3 (5/8; 63%). Thus, the fraction of homozygous mutations for
the 11 different NPHP-causing genes together was 70% (67/96)
and ranged from 30–100%. The other patients had compound
heterozygous mutations in these genes. In patients with NPHP
there was some bias towards selection of consanguineous kindred.
However, we have also ascertained a worldwide cohort of 404
families with SRNS for mutation analysis in the genes NPHS1 and
NPHS2 without selection for consanguineous kindred. In 73/404
(18%) of these families we detected both mutated alleles of NPHS2.
Thirty-three of the 73 (45%) had homozygous mutations [4].
NPHS1 mutations were detected in 36 of 86 (42%) families with
congenital nephrotic syndrome. Twenty-four of the 36 (67%) had
homozygous mutations (Heeringa, unpublished). We thus demon-
strate that for 13 different recessive disease genes a very high
fraction (124/205; 60%) had homozygous mutations, although
ascertainment was mostly by self-recruitment for mutation analysis
and not specifically directed at patients from a consanguineous
background. We conclude that in a large proportion of patients
from worldwide cohorts with mutations in various rare recessive
disease genes homozygosity mapping is potentially feasible.
Homozygous Mutations Map to Homozygosity Peaks
We next tested the assumption that homozygous mutations of
recessive disease genes are virtually always localized in segments of
contiguous homozygous SNP markers derived from a (distant)
common ancestor and can therefore be located by homozygosity
mapping. The rationale of homozygosity mapping is summarized
Mapping in Outbred Individuals
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detectable size of homozygous segments as short segments will
reduce the number of candidate genes. From our worldwide
cohort of 124 families with known homozygous mutations in 13
different recessive genes (NPHP1-9, AHI1, MKS3, NPHS1 and
NPHS2) we selected for total genomes scan 72 patients from 54
different families that had sufficient DNA available. The selected
families represented the entire spectrum of consanguinity from first
degree cousin relations to outbred populations. Families, patients,
and their homozygous mutations are listed in Table S1.
Following total genome search by homozygosity mapping
primarily using 250 K SNP arrays we plotted for each individual
‘‘homozygosity profiles’’ across the genome as defined in Figure
S1. Examples are given in Figure 2 for three individuals with
homozygous mutations in NPHP3, NPHP2, and NPHP5, respec-
tively. Homozygosity plots of all 72 cases are available from the
authors. Generation of homozygosity profiles suggested that the
number of cZLR peaks per genome reflected the degree of
consanguinity of an individual (Figure 2). For example, individual
A14-2 who is from a consanguineous Venezuelan kindred with 17
documented consanguinity loops, exhibited 28 cZLR peaks
(Figure 2A), whereas individual A8-1, who is not aware of
consanguinity but originates from a geographic region with
frequent consanguinity (Turkey) exhibited 12 cZLR peaks
(Figure 2B). Only one of the 12 cZLR peaks colocalized with
one of the 9 different NPHP loci. This was the NPHP2 locus, in
which the patient has a homozygous disease causing mutation
(Figure 2B). This demonstrates that in diseases with multiple
responsible loci the generation of a homozygosity profile can help
select the locus relevant for mutation analysis from a high number
of alternative disease loci. Thus, homozygosity profiles will reduce
the number of exons to be examined in molecular genetic
diagnostics. In the example given it was reduced from 220 exons
for NPHP1 through NPHP9 to 16 exons for NPHP2 only. In
contrast, individual F399-1, who originates from a geographic
region where consanguinity is rare (Germany) exhibited only one
single cZLR peak of 8.2 Mb width, which harbored the disease-
causing homozygous mutation in NPHP5 (Figure 2C). These data
gave a first indication that the number of ZLR peaks per genome
reflect the degree of consanguinity and that homozygous
mutations in outbred populations can be localized to a single
cZLR peak that is unique to an individual’s genome.
The strategy of homozygosity mapping carries the theoretical
risk that the mutation in the recessive disease gene may not be
detected in a homozygosity peak. In order to test whether
homozygous disease-causing mutations were practically always
positioned in cZLR peaks, we generated homozygosity plots as
defined in Figure S1 (see also Figure 2) of all 72 individuals from
54 families with homozygous mutations in one of the 13 different
recessive genes tested. We found that in 67 of 72 cases (93%) the
homozygous mutation of the causative gene was in fact positioned
within a cZLR peak (data available from the authors). In the five
individuals with absence of a cZLR peak the mutation was
embedded in a homozygous haplotype too short for detection (see
below). In the 13 rare recessive disease genes studied, we thus
confirmed the hypothesis that most homozygous mutations (93%)
can be mapped to a cZLR peak.
The Number of cZLR Peaks Reflects Consanguinity
To examine the relationship between the number of cZLR peaks
and degree of consanguinity we plotted the number of cZLR peaks
for each of the 72 individuals from 54 families with homozygous
disease-causing mutations (Figure 3). The number of cZLR peaks
ranged from 60 to 0 (Figure 3). When we sorted families from left to
right from highest to lowest number of cZLR peaks, the number of
cZLR peaks reflected the degree of inbreeding in each family as
follows (Figure 3): i) Families with known consanguinity (orange
highlightinginFigure3)clusteredinthe leftthirdofthe plotwiththe
number of cZLR peaks ranging from 60 to 8. Fourteen of fifteen
consanguineous families (orange) had 8 or more cZLR peaks. The
highest number of cZLR peaks was seen in the following closely
inbred families: A1337 (1
st degree cousins, Turkey), F617 (Native
American), A1175 (1
st degree cousins, Turkey), A1125 (known
consanguinity, Turkey), A364 (known consanguinity), A14 (17
consanguinity loops, Venezuela), and F3 (1
st degree cousins) [16]. ii)
Families without known consanguinity, but originating from
geographic regions where consanguinity is frequent (yellow
highlighting in Figure 3), clustered in the middle third of the plot
with, 8 of 12 families having 8 to 4 cZLR peaks. These families
originated mostly from Turkey and Arab countries (Table S1). iii)
Outbred families, i.e. families without known consanguinity and
originating from geographic regions where consanguinity is rare (no
highlighting in Figure 3), clustered in the right third of the plot with
cZLR peaks. Twenty-three of the 27 outbred families had 4 to 0
cZLR peaks (0 denoting that no cZLR peak was detected). These
families originated mostly from Western Europe and the US (Table
S1). No family from a consanguineous population had 3 or less
cZLR peaks.
We thereby demonstrated through graphical evaluation of total
genome homozygosity profile data, that the number of cZLR
peaks of individuals reflected their degree of inbreeding and
thereby the extent of homozygosity by descent. Specifically, the
number of homozygosity peaks was 8–60 in families with known
consanguinity, 4–8 in families with unknown consanguinity but
originating geographic background ‘‘at risk’’ for consanguinity,
and it was 0–4 in families from outbred populations. Homozy-
gosity profiles can therefore be viewed as ‘‘consanguinograms’’
that reflect the degree of inbreeding of an individual. The data set
generated (Figure 3) gave us the opportunity to examine the limit
of resolution for detecting short segments of homozygosity in single
individuals with homozygous disease-causing mutations from
outbred populations.
Homozygous Disease Mutations Can Be Mapped in
Single Individuals of Outbred Populations
Until now, successful gene identification by homozygosity
mapping has been mostly based on consanguineous kindred that
have multiple affected individuals. Close consanguinity of such
kindred generate homozygous segments broad enough to be
detected by SNP marker sets of low density (e.g., 50 K marker set).
The presence of multiple siblings or cousins helps refine the
candidate region to fewer cZLR peaks that overlap between
affected siblings or cousins. For example, the number of 9, 12 and
10 cZLR peaks in siblings A1538-1, -2, and -3, respectively is
reduced to 3, 4, and 5 cZLR peaks if each pair of siblings is
evaluated together and to 2 cZLR peaks if all three sibs are
evaluated together (Figure 3). However, a severe limitation to
successful positional cloning of recessive disease genes by
homozygosity mapping lies in the fact that sufficient numbers of
consanguineous kindred with multiple affecteds and mutation of
the same gene are very hard to ascertain. In our 16-year
experience in worldwide recruitment of 1,069 patients with
NPHP, non-consanguineous single cases (n=918) were 6-times
as frequent as consanguineous cases (n=151). In 595 patients with
SRNS and mutations in recessive disease-causing genes the
ascertainment of non-consanguineous single cases (n=512) was
also about 6-times as high as consanguineous cases (n=83).
Therefore, the ability to employ individuals from outbred
Mapping in Outbred Individuals
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gene discovery.
Another strong limitation to gene identification is imposed by
the experience that studies of consanguineous kindred result in
segments of homozygosity that are too numerous and too large
and contain too many positional candidates for efficient gene
identification by mutation analysis. For instance, in our worldwide
cohort individuals from consanguineous background had 4–60
cZLR peaks (Figure 3). These homozygous segments contained
hundreds of positional candidate genes. Because of both
limitations we wanted to evaluate whether gene identification by
homozygosity mapping is possible in single individuals from
outbred populations. Using a medium resolution SNP marker set
(250 K) we were able to detect homozygous segments that contain
the disease-causing mutations in single individuals from outbred
populations as shown in Figure 3:
With the exception of 4 families (A1218, A646, F1158, and
A825), all other 23 outbred families exhibited 4 or less cZLR peaks
(Figure 3). In 2 of the 3 outbred families with 4 cZLR peaks,
calculation of both affected individuals together reduced the
number of cZLR peak from 4 and 3 cZLR peaks to 2 cZLR peaks
(A237) and from 4 and 2 peaks to 1 cZLR peak (F60-61). Four
outbred families had 3 cZLR peaks (F138, F456, F50, and F1183).
Seven outbred individuals exhibited only 2 cZLR peaks (A762,
F53, A1298, A567, A7, F54, and A1338) (Figure 3). In these
individuals the cZLR peak that contained the homozygous gene
mutation had a median size of 8.3 Mb (range 2.4 - 40.1 Mb)
(Figure 3, insert).
Most interestingly, 4 outbred families exhibited only 1 cZLR
peak (F399, A1730, F30_10G, and F408) (Figure 3). These peaks,
which contained the homozygous gene mutation, had a median
size of only 2.7 Mb (range 2.1–8.25). A genomic segment of
Figure 3. Detection limit for recessive disease loci in 72 affected individuals of 54 families with known homozygous disease-
causing mutations. Total genome search by homozygosity mapping was performed by typing 250 K SNP arrays in 72 individuals of 54 families with
known homozygous mutations in 13 different autosomal recessive kidney disease genes. Under the hypothesis of identity by descent, total genome
homozygosity profiles were calculated as described in Methods. The numbers of cZLR peaks (Figure S1) were plotted per family. Families were
ordered from the highest to the lowest number of cZLR peaks from left to right. On the X-axis orange highlighting is used for 15 families with known
consanguinity, yellow highlighting for 12 families with no known consanguinity but originating from a population with frequent consanguinity, and
no highlighting (white) for 27 families from outbred populations. Family number is preceded by one or two asterisks if data were generated by 50 K
or 10 K SNP arrays, respectively. Filled circles denote affected individuals with homozygous mutations (siblings numbered as 1, 2, or 3 to the left or
right), open circles denote father (F) or mother (M). Dashes denote number of peaks for two affected siblings calculated together (individual numbers
shown above dashes), filled triangles for three siblings calculated together (individual numbers shown below triangle). Note that families with known
consanguinity (orange) cluster in the left third of the plot with cZLR peaks ranging from 60 to 8, families without known consanguinity but from a
populations, in which consanguinity is frequent (yellow) cluster in the middle with number of cZLR peaks ranging from 8 to 4, whereas families from
outbred populations (no highlighting) cluster in the right third of the plot with cZLR peaks ranging from 4 to 0. Inset: In families from outbred
populations that yielded 2 or fewer cZLR peaks, cumulative physical width in Mb for all cZLR peaks together is plotted (red, with axis on the right;
exponential fit; if no peak was detected extent of homozygous markers at the gene locus is given). The cut off at which no cZLR peak was detectable
was for a cZLR peak width of 2.1 Mb (see also Table 1). Note that parents of family F30_10G are known to be related 10 generations back, and that
F190_HET represents an outbred control individual with a known compound heterozygous mutation in MKS3.
doi:10.1371/journal.pgen.1000353.g003
Mapping in Outbred Individuals
PLoS Genetics | www.plosgenetics.org 6 January 2009 | Volume 5 | Issue 1 | e10003532.1 Mb is equivalent to an average of 16 candidate genes, a
number of genes that permits gene identification by exon
sequencing in candidate genes. For comparison, we have so far
successfully identified disease genes by mutation analysis of all
exons within intervals of 8.7 Mb (57 genes) in NPHP5 [17],
1.5 Mb (9 genes) in NPHP6 [18], 0.94 Mb (7 genes) in NPHP3
[19], 0.90 Mb (11 genes) in BSND [20], 0.70 Mb (6 genes) in
NPHP4 [21], and 4.0 Mb (43 genes) in PLCE1 [22]. We thereby
demonstrated that we were able to detect a cZLR signal of
‘‘homozygosity by descent from the disease allele’’ above the
background of ‘‘homozygosity by descent from haplotype blocks
common to the outbred population’’. To be detectable, the former
would have to be more recent and therefore reside on a longer
segment of homozygosity than the latter.
Finally, in 5 families (F409, A159, A1686, A1685, and A887), in
whom the known homozygous mutation was positioned in
homozygous segments of less than 2.1 Mb, we did not obtain
any cZLR peak (see Table 1 and inset in Figure 3). Therefore, we
conclude that the limit for detecting a homozygous segment in
single outbred individuals with homozygous disease-causing
mutations using this technique was 2.1 Mb. Three observations
further substantiate this detection limit: i) We demonstrated for the
first time that the R138Q mutation of NPHS2 does in fact
represent a founder mutation as it occurs on identical haplotypes
(Figure S2). It was detected within a homozygous interval of
2.7 Mb (212 SNPs) in both individuals of family A1730 (Table 1
and Figure S2). It was also detected within 2.3 Mb of
homozygosity in families A237, and A825, who had additional
cZLR peaks on other chromosomes (Figure S2). However, the
R138Q mutation was not detected within homozygous intervals of
1.2 Mb, 1.2 Mb, and 0.70 Mb, in families A159, A1686, and
A887, respectively (Table 1 and inset in Figure 3). ii) In family F30
a single cZLR peak of 2.1 Mb width bearing a homozygous
NPHP4 mutation was detected in individual F30-1, but not within
the sibling’s (F30-2) interval of 1.14 Mb, which is shorter due to a
recombination in the mother’s meiosis (Table 1). We documented
that the parents of F30 are related 10 generations ago. This gives
an example of the ‘‘remoteness’’ of inbreeding that leads to
homozygous intervals in the order of ,1–2 Mb [23]. iii) Families
F408 and F409 bear the same homozygous mutation (F142fsX14)
in NPHP5 and originate from the same geographic region in
Switzerland. We demonstrate that this mutation is embedded in a
shared haplotype (Figure S3). Whereas we detected the 5.18 Mb
homozygous interval as a single cZLR peak in F408, the shorter
haplotype of 0.65 Mb in F409 was not detected as a cZLR peak
(Table 1 and Figure S3). In 28 unrelated individuals with recessive
disease from outbred background with known homozygous
mutations in recessive genes we failed to detect a ‘‘ZLR peak of
homozygosity’’ in 6 (21%). In all of these patients the homozygous
mutation resided in a homozygous segment of less than 2.1 Mb
(Figure 3 and Table 1). Thus, the limit of detection of a
homozygous mutation using our homozygosity mapping strategy
was at 2.1 Mb (Table 1, Figures S2 and S3). It is remarkable
however, that even if homozygous mutations were not detected as
a cZLR peak they were always embedded in a homozygous
haplotype of .0.65 Mb. This indicates that it may be possible to
further improve the sensitivity of the approach.
False Positive cZLR Peaks Are Rare
The sensitivity for detecting a cZLR peak in an individual with a
homozygous mutation was 93% (67/72) for all 72 patients (see
above). It was 76% (16/21) if only the 21 outbred individuals with
4 or less cZRL peaks were evaluated. In order to assess the
specificity of the method, i.e. whether or not cZLR peaks occur
frequently as ‘‘false positives’’ in individuals without homozygous
mutations in outbred populations, we examined 20 parents of
affected individuals with a homozygous mutation, as parents are
obligate heterogygotes. Thirteen of 20 such parents had no cZLR
peak, equivalent to a specificity of 65%. Five parents had one
cZLR peak, one parent had 2 peaks, and one father had 7 peaks,
being most likely from unknown consanguineous background
himself (Figure 3). This specificity of 65% should not pose a
problem for gene identification, since the likelihood that a false
posititive cZLR peak of a few Mb size will colocalize by chance for
two individuals, thereby pointing to a false candidate locus, is in
the order of only 1:1,000.
Table 1. Detection limit of homozygosity by descent using 250 K SNP array.
Individual with known
homozygous mutation
Gene with homozygous
mutation
Number of cZLR
peaks detected
Width of cZLR
peak [Mb]
Number of
homozygous SNPs
F399-1 NPHP5 1 *8.25 767
A1730-1 NPHS2 1 *2.70 212
A1730-2 NPHS2 1 *2.70 212
F30-1 NPHP4 1 *2.10 222
F30-2 NPHP4 0 1.14 125
F408 NPHP5 1 *5.18 420
F409 NPHP5 0 0.65 48
A159 NPHS2 0 1.20 108
A1686 NPHS2 0 1.20 89
A1685-1 NPHP8 0 0.70 49
A1685-2 NPHP8 0 0.70 49
A887 NPHS2 0 0.68 47
F190 nc 0N A N A
For individuals, in which total genome search yielded a single cZLR peak (homozygosity peak) that contains the homozygous disease-causing mutation, the width of the
cZLR peak is marked with an asterisk. Note that the detection limit for homozygosity by descent was at 2.10 Mb.
cZLR, consistent likelihood ratio z-score (see Figure S1); NA, not applicable; nc, negative control individual with a known compound heterozygous mutation.
doi:10.1371/journal.pgen.1000353.t001
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mutation in outbred single affecteds with mutations in a recessive
disease gene using the approach described here, we prospectively
performed 250 k SNP DNA microarray analysis in 24 unrelated
outbred patients with infantile nephrotic syndrome, which is
known to be caused by NPHS1 mutations in 22.5% of cases (18/
80) [3] and by PLCE1 mutations in 28% of cases (10/35) [24]. We
obtained the following distribution for the number of ZLR peaks
of homozygosity per patient: 0, 1, 2, 4, and 6 peaks in 9, 4, 8, 1,
and 2 patients, respectively. In all 24 patients mutation analysis
was performed by exon PCR of all NPHS1 and PLCE1 exons. We
identified both causative mutations in 21% (5/24) of these patients
(4 patients had NPHS1 mutations and 1 patient had a PLCE1
mutation). In the 15 of 24 outbred patients that had ZLR peaks of
homozygosity, we identified homozygous mutations in 27% (4/15)
of these patients (3 patients with a homozygous NPHS1 mutation
and 1 patient with a homozygous PLCE1 mutation). As expected,
these 4 patients with homozygous mutations had a ZLR peak of
homozygosity at the locus of their mutation. However 1 additional
patient had a compound heterozygous mutation of NPHS1
although we observed 2 ZLR peaks of homozygosity at different
loci. This patient represents an example of a ‘‘false positive result’’
in the homozygosity mapping approach. We conclude that the
fraction of homozygous mutations detected in NPHS1 and PLCE1
in patients with infantile nephrotic syndrome (27%) using the
homozygosity mapping approach in outbred individuals prospec-
tively was similar to the one reported by diagnostic sequencing
(22.5% for NPHS1 and 28% for PLCE1).
We conclude that homozygosity mapping of recessive disease
genes is possible in single individuals from outbred populations.
The current resolution is at ,2.1 Mb, containing an average of
only 16 candidate genes.
Discussion
In a worldwide cohort of 72 individuals from 54 families with
homozygous mutations of 13 different autosomal recessive disease
genes we here describe a strategy for the detection of disease loci by
homozgosity mapping using 250 K SNP arrays. The number of
cZLR peaks reflected the degree of inbreeding and thereby the
extent of homozygosity by descent. We were able to detect the locus
of the disease-causing mutation in 93% of cases. We demonstrate
for the first time in a systematic way that loci of homozygous
mutations in recessive disease-causing genes can be detected in
singleindividuals fromoutbred populations. Thedetectionlimit was
at 2.1 Mb of a segment for homozygosity by descent.
Recently, data was published on segments of homozygosity by
descent (‘‘runs of homozygosity, ROH’’) from inbred and outbred
populations [25]. The outbred population studied by McQuillan et
al. that most closely resembles our outbred population is the
‘‘HapMap CEU’’ population. The CEU population is a
Northwest-European-derived population from Utah, USA, which
represents the founders of the CEPH individuals (Centre d’Etude
du Polymorphisme Humain), in which broad genetic studies have
been performed for decades. Interestingly, ROH of ,2.5 Mb size
were detected in close to 100% of CEU individuals, whereas ROH
of 2.5–5.9 Mb were found in only 22%, and ROH for 5–9.9 Mb
in only 5% of individuals. These data compare with our study as
follows: Using the calling method for ‘‘ZLR peaks of homozygos-
ity’’ as described in our study, we did not detect any peaks if a
known mutation resided in a homozygous segment of less than
2.7 Mb (with one exception of a peak detected at 2.1 Mb) (see
Table 1). This implies that the high background of ROH,2.5 Mb
seen in the study by McQuillan et al. in outbred individuals would
not pose a problem to our approach. Our study would rather have
to be compared (in randomly selected outbred individuals) to a
rate of background ‘‘ZLR peaks of homozygosity’’ of 22% for 2.5–
5.9 Mb ROH and with 5% for 5–9.9 Mb ROH found in the
McQuillan study. In our study, for 18 individuals that self-
described as ‘‘non-consanguineous’’ and exhibited ‘‘ZLR peaks of
homozygosity’’, 11 of them (61%) had 1 or 2 ‘‘ZLR peaks’’
spanning 2.1–11.5 Mb of total genomic width (Figure 3). Thus, we
found a very large enrichment of ROH in individuals with a
known homozygous mutation in a recessive gene compared to
randomly-selected healthy control subjects.
If feasibility of gene identification is considered in this setting, a
span of genomic sequence of 12 Mb would harbor on average less
than 1,800 exons (12 Mb66 genes/1 Mb625 exons per gene).
Using new exon capture techniques followed by large-scale
sequencing [26] it will be feasible to capture candidate regions
from more than 13 such individuals on a single DNA capture
microarray using the current technology that allows capture and
sequencing of a total of 5 Mb of sequence on one DNA capture
microarray (13 individuals61,800 exons6200 bp/exon=
4.68 Mb).
The Utility of the Approach
These data are, to our knowledge, the first to quantify for a large
cohort of patients with known homozygous mutations in a high
number of different recessive disease-causing genes the extent of
homozygosity by descent and its detection limit in outbred
populations. Our findings have the potential to strongly facilitate
the identification of recessive disease-causing genes by overcoming
some of its major impediments: i) First, large cohorts of
consanguineous pedigrees are very difficult to ascertain, whereas
most pediatric specialty clinics have direct access to sufficient
numbers of single individuals of rare pediatric diseases. ii) Second,
homozygosity mapping in consanguineous kindred leads to large
candidate regions that usually contain too many positional
candidate genes to allow for gene identification by mutation
analysis. Here we demonstrate that homozygosity mapping can be
performed in single affecteds from outbred populations yielding a
single cZLR peak per genome. We were able to map the disease-
causing gene to single peaks representing segments of homozy-
gosity that were as short as 2.1 Mb, which would contain 16 genes
on average. For positional cloning of novel recessive disease genes
this strategy offers a reduction of complexity of three orders of
magnitude, i.e. from 3,300 Mb to ,3.3 Mb or from 25,000 genes
to ,25 genes. This reduction makes gene discovery by mutation
analysis feasible, either by exon sequencing or large-scale
sequencing using emerging techniques.
Additionally, in regions of homozygosity affected individuals
from different families that originate from the same geographic
region may, within the homozygous haplotype, be identical by
descent from an unknown common ancestor. Candidate gene
analysis can then be focused on this short interval under the
hypothesis that both families might share the same disease allele,
as we show for the NPHS2 mutation R138Q (Figure S2) and for an
NPHP5 founder mutation (Figure S3). This approach has also been
useful in the identification of the NPHP6/CEP290 gene [18].
Application to Molecular Genetic Diagnostics
The strategy described here is especially useful in situations of
pronounced genetic locus heterogeneity, in which similar autoso-
mal recessive phenotypes may be caused by a high number of
different genes. In this situation a first run of homozygosity
mapping will show whether the individual most likely carries a
homozygous disease mutation by presence of one or more cZLR
Mapping in Outbred Individuals
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restricted to genes that are positioned in a cZLR peak of the
individual. An example for NPHP is given in Figure 2B. Even if in
the near future rapid and cost-effective sequencing of a person’s
genome will be possible, which has been referred to as the ‘‘$1,000
genome’’, homozygosity mapping in outbred populations will be a
valuable first step of molecular genetic diagnostics in recessive
diseases for the following reason: It generates the hypothesis that a
disease-causing homozygous mutation will be found in a
homozygosity peak and nowhere else, thereby reducing the high
number of difficult-to-interpret sequence changes found outside
cZLR peaks.
Improving the Detection Rate
Our data show that the approach of homozygosity mapping in
outbred individuals at a marker density of 250 K has not reached
its theoretical limit of refinement yet, as we found some
homozygous disease alleles embedded in haplotypes as short as
0.65 Mb equivalent to only 48 SNP of the 250 K array (Table 1,
Figures S2 and S3). The following measures may increase the
likelihood of detecting even shorter unique homozygous segments
that contain the disease-causing mutation in single individuals
from outbred populations: i) When increasing the density of
markers evaluated in multipoint calculations to more than 1
marker per 100,000 nucleotides, additional homozygosity peaks
appear as ‘‘background’’. This background is most likely due to
non-informative alleles (identically homozygous in both parents).
Linkage calculation together with parental genotypes will allow
exclusion of these markers, thereby reducing the number of false
positive cZLR peaks. This will permit increasing the number of
markers evaluated, allowing detection of even smaller homozygous
loci. iii) SNP arrays with higher density are now available (e.g. 1
Mill. SNPs). They contain HapMap-derived SNPs that are
potentially more informative. However, as we observed a relatively
high rate (,4%) of false heterozygous allele calls in the 250 K SNP
arrays (see Methods), the utility of higher density SNPs for
homozygosity mapping in outbred individuals will need to be
tested first. The individuals tested here, in whom we showed that
homozygous mutations are embedded in a short homozygous
haplotype by descent, provide a perfect resource for testing the
limitations of higher resolution SNP arrays for homozygosity
mapping in outbred individuals. As inclusion of parents of an
affected individual in the total genome haplotype analysis
establishes the origin of the paternal and maternal haplotypes, a
data base of disease-allele specific haplotypes would permit even
detection of known mutations by their haplotype in individuals
with compound heterozygous mutations in the future.
The new strategy of homozygosity mapping in single outbred
individuals described here has a strong potential of accelerating
the discovery of novel recessive disease genes as a critical step
towards elucidating the pathogenesis of a wide variety of pediatric
disorders independent of organ system involved.
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Figure S1 Homozygosity profiles reveal loci of homozygous
mutations in recessive disease genes.
Found at: doi:10.1371/journal.pgen.1000353.s001 (11.18 MB
TIF)
Figure S2 The European ‘‘founder’’ mutation R138Q of
NPHS2 occurs on a shared haplotype by descent from a common
ancestor.
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Figure S3 The NPHP5 mutation F142fsX147 occurs on a
shared haplotype.
Found at: doi:10.1371/journal.pgen.1000353.s003 (2.48 MB PDF)
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